The Missing Link in Ocular Therapeutics: Precision Delivery

Breakthrough therapies cannot succeed without reliable access to the posterior eye. Current delivery methods limit efficacy, consistency, and patient outcomes.

The Problem

Most vision-threatening diseases originate in the posterior segment, particularly the macula, yet current delivery approaches are fundamentally constrained:

• Intravitreal injections lack targeted posterior distribution

• Subretinal surgery is invasive, complex, and not scalable

• Inconsistent suprachoroidal access limits reproducibility

• Drug loss and variability reduce effective dosing

• Patient burden remains high with repeated treatments.

The Opportunity

The suprachoroidal space (SCS) represents a critical but underutilized pathway.

The SCS enables:

• Circumferential distribution around the eye

• Direct access toward the posterior pole and macula

• Potential for improved therapeutic targeting

• Reduced systemic exposure

But existing tools have not reliably unlocked this space.

Why Now

Therapeutics have advanced. Delivery has not.

• Gene therapies, biologics, and sustained treatments are emerging

• These therapies require precise, efficient delivery

• Current devices were not designed for these modalities

This creates a clear mismatch between therapy and delivery.